Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12203616 | 0.74 | ADRA2A (0.38) | ADRA2ATSHRSIGMAR1KDM1ABACE1 | |
| SCHEMBL25966669 | 0.74 | ADRA2A (0.38) | ADRA2ATSHRSIGMAR1SMN1; SMN2KDM1A | |
| SCHEMBL24170217 | 0.74 | ADRA2A (0.38) | ADRA2ATSHRSIGMAR1SMN1; SMN2KDM1A | |
| SCHEMBL597727 | 0.74 | ADRA2A (0.43) | ADRA2ATSHRSIGMAR1NOTUMKDM1A | |
| SCHEMBL21447692 | 0.73 | BRD4 (0.38) | KDM1A | |
| SCHEMBL22152402 | 0.73 | ALOX15 (0.38) | — | |
| SCHEMBL20333881 | 0.73 | BRD4 (0.38) | KDM1A | |
| SCHEMBL20351801 | 0.72 | PNMT (0.38) | MAOB | |
| SCHEMBL13199764 | 0.71 | ADRA2A (0.41) | ADRA2ATSHRSIGMAR1NOTUMKDM1A | |
| SCHEMBL20404660 | 0.71 | KDM1A (0.42) | ADRA2ATSHRSIGMAR1NOTUMKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ADRA2A 2107/4885TSHR 4477/4885SIGMAR1 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.